Search results

4G Clinical is a global leader in randomisation and trial supply management and supply forecasting optimisation software for the life sciences industry, offering a fully cloud-based, 100% configurable solution using natural language processing to accelerate clinical trials.

Immune response on a chip!

ZETA is an end-to-end solution provider and innovation leader for pharma & biotech and specializes in the design, automation, and qualification of customer-specific systems for pharmaceutical manufacturing. ZETA is an EPCMv contractor, drives digtialization and develops decarbonization strategies.

TissueLabs is a Swiss biotech pioneering biofabrication, developing 3D bioprinters, tissue-specific hydrogels, and engineered tissues. Supporting research, drug testing, and regenerative medicine, its long-term vision is to create the first transplantable bioartificial heart.

Limula is a Life Science Tools company based in Lausanne, Switzerland. We combine cell therapy process development and precision engineering to offer a fully closed and automated platform for the production of CAR-T and other highly-personalised treatments.

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies. We leverage our world-class protein engineering & conjugation platform to generate novel protein therapeutics for cancer and other indications. Bright Peak is located in Basel and San Diego.

Athebio develops ultra-stable biotherapeutics using proprietary Athebody® DARPin molecules with high affinity and specificity. We partner on radiotherapeutics, T cell engagers, targeted delivery (LNP/AAV/oligo) and affinity ligands, enabling breakthrough therapeutic strategies.

At Alithea Genomics we develop, produce and commercialize cutting-edge solutions for drug and biomarker discovery based on gene expression. Our products provide high throughput and cost-efficiency, which is ideal for large-scale projects such as drug screening and biomarker discovery.

Novochizol SA researches and develops applications of Novochizol, a unique chitosan nanoparticle technology that yields different carriers of small molecules, peptides, nucleic acids and proteins for sustained, localized delivery to any living tissue, with intracellular targeting potential.

GlycoEra is developing biologics to selectively degrade autoimmune disease causing circulating proteins rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies.

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland and abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.

cellvie is pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism. The first application will be in ischemia-reperfusion injury, specifically in kidney transplantation and heart attack patients, with the aim to develop a broad platform.

A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indications in IBD, dysbiosis induced by antibiotic treatments and unhealthy diet, and as enhancer in cancer immunotherapy.

Gut-restricted metabolic therapies. Validated platform with 3 preclinical proof-of-concepts. Established as a private company (AG) in Basel in 2019. Secured a partnership with Nestlé Health Science for one asset. Raised CHF 10M in equity and non-dilutive funding. Raising Series A.

GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform and pipeline of molecules targeting brain glial cells to restore brain metabolism deficits in neurological diseases linked to brain metabolism dysfunction.

DiNAQOR has developed a proprietary technology platform and manufacturing capabilities designed to overcome the challenges and limitations of early-stage gene therapy development.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development platform targeting neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).

Linkster engineers delivery-first medicines in oncology. Our proprietary VHH platform (Sybody®) and world's first in vivo HT-discovery engine (Flycode®) de-risk complex targets to generate precision ADCs and multispecifics at the earliest stages.

Cancer Research and Biotechnology AG (CRB) is a Swiss biopharma company developing novel small molecule treatments for pancreatic cancer, triple-negative breast cancer, and colon cancer. CRB091 is a non-toxic therapy targeting triple-negative breast cancer (TNBC) with a first-in-human submission planned for 2

QBDC GmbH is a consultancy company in the biotech and pharma industry providing support for module 3 development from DNA to final drug product, from facility design phase to process validation. Besides our services, QBDC provides solutions for affordable GMP-compliant data and document management.

At Nagi Bioscience we create cutting-edge biological testing solutions that empower scientists with actionable data to fuel discoveries in a faster, efficient, and ethical way. Our Organism-on-Chip platform, SydLab™ One, enables automated in vivo testing at the in vitro scale in high-throughput.

MesenFlow Technologies has developed a service platform to meet the demands of modern drug development. It has been designed to accelerate the development process and provide solutions to common problems associated with species cross-reactivity, animal testing and understanding human disease.

We focus our efforts on supporting injection devices, medical devices, IVD, combination product developments and compliance projects for our pharmaceutical and biotech clients, who either lack resources familiar with medical device development or wish to complement their existing resources.

Orion Biotechnology is a Swiss/Canadian clinical stage company. Orion is the only company with a novel approach to drug peptide and protein GPCRs. Our platform offers one of the fastest drug discovery solutions in industry to target peptidergic GPCRs. Orion has a strong and diverse pipeline.

International, Swiss and MENA based boutique consultancy providing customized expert advice and (hands-on) implementation support for life-sciences and related industries based on diversified know-how of three continents and extended network following our credo “Knowledge - network - solutions”.

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.

Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.

Artidis® is a pioneering clinical stage health technology company that aims to set the gold standard in tissue analysis and therapy optimization. Artidis focuses its efforts on solid tumors to enhance responses to chemo, immuno, and cell therapies, driving precision in cancer care.

abc biopply AG is pioneering NAM technologies and organoid CRO services that boost in vitro studies for drug discovery and development to IND relevance using its proprietary 3D CoSeedis Multi-Organoid in chip Technology™ on clinically relevant disease models (oncology, neurology, obesity and others).

Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy.

TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies.

PharmaBiome has developed a drug development platform for targeted microbiome therapeutics, combining dynamic microbiome analysis and co-cultivation-based assembly technology. By actively engineering composition and activity of our multi-strain consortia we solve current translational shortcomings.

There is a new kit on the block. Swiss start-up NEMIS Technologies AG specialises in the development of simple, safe, and on-site pathogen testing solutions. Its detection test for Listeria monocytogenes is already commercially available in Switzerland, France, and Spain.

Wyss Zurich is a joint accelerator of ETH & University of Zurich. Our mission is to drive the clinical translation of outstanding scientific discoveries into new therapies for patients and innovations in the fields of regenerative medicine and robotics, and hybrid technologies in these fields.

Xenometrix delivers innovative, reliable bioassays for the safety assessment of test compounds in mutagenesis, genotoxicity, endocrine activity and explants for absorption tests (IVPT), combining Swiss quality, scientific expertise, and customer-focused support for global research, regulatory needs.

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.

TOLREMO engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies.

Synple Chem was founded to develop new easy to use automated laboratory equipment for chemistry research labs.

The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments based on live bacteria. T3 Pharmaceuticals was acquired by Boehringer Ingelheim on 22 November 2023.

Tepthera is a spin off from the ETH Zurich focusing on product development in the field of cancer immunotherapy, autoimmune- and infectious diseases.

Shimadzu Corporation, one of the world's largest instrument manufacturers with annual sales of more than $3 billion, focuses on providing integrated solutions for life science to accelerate the progress of biotechnology in research and development through its Shimadzu Biotech brand.

SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 750 institutions in over 70 countries.  Our network advances data-driven medicine to improve health outcomes and economics worldwide.

SpacePharma provides researcher, institutes and commercial companies an easy and affordable access to the microgravity environment. Our novel technology enables researchers to perform complex chemical and biological experiments with our proven cutting-edge remote-control technology and labs in space

Securecell is an innovator for both the biotech and medtech space. Developing use-case applications for automated bioprocessing and smart pharmacoligical facilities, as well as the transformative applications of digital technologies to help hospitals and life scientists solve next-world problems.

Regen Lab is a global leader in products for autologous regenerative medicine based on freshly prepared platelet rich plasma from the patient’s own blood, used either alone or combination with hyaluronic acid or other fresh autologous cells from the patient’s fat or bone marrow.

PreComb Therapeutics AG develops a new 3D drug testing platform for cancer patients. The automated profiling device will allow pharma R&D and clinicians to perform personalized profiling of cancer drugs and drug combinations directly on site and provides broad drug response data for in-depth mining.

As Swiss branch of Promega Corp, Promega AG offers local scientific expertise for 4000+ products covering genomics, proteomics and cell analysis. Promega is a global leader in providing innovative solutions for drug discovery, basic research, human identification, diagnostics and food/water testing.

OMNI Life Science GmbH is located in Basel, Switzerland. We are your local partner for solutions in cell-based assays and are dedicated to provide innovative solutions for research in life science.

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Novassay is a biotech active in the area of Ion Channel therapeutics with focus in neuropathic pain and Oncology. We have a portfolio of assets currently in development (approaching IND stage) and interested in partnering and R&D collaborations.

Novigenix AI is a TechBio that powers precision medicine through its proprietary AI-enabled liquid biopsy mRNA platform, LITOSeek, to map immune-response dynamics across disease onset and progression—turning biology into actionable insights for therapy development.

Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018. We now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a novel class of DARPin therapeutics, a novel class of custom-built protein drugs, for medical challenges that other drug modalities cannot readily address.

Memo Therapeutics AG develops therapeutic antibodies for viral infections and cancer. Lead asset potravitug targets BKV in kidney transplant recipients; Phase II SAFE KIDNEY data, presented in Nov 2025, support a planned Phase III start in 2026. MTx is also building an oncology discovery pipeline.

Microsphere (MS) is a CDMO focused on new developments, cGMP manufacturing, R&D, analytical and regulatory support. MS is able to address complex challenges, including formulations for poorly water-soluble drugs, considering the extensive expertise in Spray Drying and Capsule Filling.

LubioScience is the biggest lifescience reagents & services platform in Switzerland. Representing some of the world’s most recognized brands, we provide over 5 million products from more than 120 suppliers and pride ourselves in working with most Swiss biotech companies & start-ups.

Lunaphore has developed an innovative device for cancer tissue diagnostics. Its award-winning technology based on microfluidics aims to achieve faster & more precise results than current techniques. It was founded in 2004 with the vision of bringing –omics like approaches to tissue diagnostics. Lunaphor

Life Technologies Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community.

Kinematica is a mechanical engineering company from Lucerne. We have our expertise in the field of homogenization and dispersion equipment form lab to production scale. We focus on close collaboration with our customer to built and scale equipment on request - for homogenization perfected.

Based on the liposomal technology platform, InnoMedica has built a diversified pipeline with lead compounds in oncology and neurodegenerative diseases. Clinical trials for the treatment of breast cancer as well as Parkinson's disease are conducted in Swiss hospitals.

INOFEA empowers enzymes. We make them much more active, resistant and long-lasting. We use our innovative enzzen® platform technology to generate multiple enzyme products for the pharma, food, specialty chemicals and consumer markets. Our empowered enzzen-enzymes are mainly used for biocatalysis, continuous

InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding healthy and diseased human physiology in vitro.

InterAx is a drug discovery firm spun out of ETHZ. Its Deep Signal platform combines AI with mechanistic cell signaling models to predict how drugs behave inside cells — designing medicines with better efficacy and fewer side effects. Pipeline spans metabolism and oncology, with pharma partnerships.

IBR Inc. is a GxP-compliant CRO offering advanced bioanalytical services for pre-clinical and clinical development of antibodies, biologics, biosimilars, antibody-drug conjugates and vaccines. The services include bioanalytics for product release under GMP.

Geneva Biotech market a portfolio of viral and nonviral DNA delivery systems that provide new and better ways to deliver DNA into cells. Our Sur Access consulting arm provides biotech investment advisory and due diligence, evaluating asset, pricing, and revenue potential for rare diseases.

evitria provides recombinant antibody production services based on CHO transient expression, focusing on bispecific, Fc-silenced, and afucosylated antibody formats. With over 140,000 transfections, we are a trusted partner for biotech and pharma worldwide.

ExcellGene is a CMO/CRO/CDO providing services and production in the field of recombinant biologics made with animal cells in bioreactors (DNA to product), such as proteins and virus vectors (AAV). Numerous innovations assure high yield, fast development time and early entry to clinic.

CSL (ASX:CSL; USOTC:CSLLY) – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – is a global biotechnology leader that develops and delivers innovative lifesaving medicines, protects public health and helps people with life-threatening medical conditions live full lives.

The Culture Collection of Switzerland (CCOS) is the Swiss national public culture collection for microorganisms and supports the life sciences community with biological material, back up storage and services.

CEBIS International is a Swiss based global patient-centric contract research organization (CRO). CEBIS is a full service CRO and provides clinical stage, regulatory and market entry support to biotech companies in 29 countries: all European countries, Brazil, India, China and USA.

CDR-Life develops highly targeted T cell engagers (TCEs) for the treatment of solid cancers and autoimmune diseases. In early clinical development and backed by leading cross-Atlantic investors, our team is committed to bringing life-changing, disease-modifying medicines to patients globally.

Securing life sciences supply chains. Complex chemicals, peptides and key biologics: products, services and innovation. Biosynth is a supplier of critical materials with chemicals on the milligram to ton scale, with peptides at mg to multikilogram scale. ISO 9001 and GMP facilities.

BioVersys AG is a privately held Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation.

BioArk drives innovation and business growth from early stages to commercialization. With two technology parks in Valais and over 10,000 jobs, our ecosystem offers cutting-edge facilities, expert coaching, funding support, and a strong industrial and scientific network.

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins. It is a cutting-edge and mature solution for oral formulations not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies.

Bio-Rad Laboratories continues to play a leading role in the advancement of scientific discovery by offering a broad range of innovative tools and services to the life science research and clinical diagnostics markets.

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.

AC Immune SA is a clinical-stage biopharma that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and NeuroOrphan indications. The company has two clinically validated technology platforms, SupraAntigen® and Morphomer®.

Activen – a Remora Venture – is a Swiss biotech company dedicated to the discovery and the marketing of natural miniproteins™ as a new class of actives for the dermo-cosmetic industry.